Vascular endothelial growth factor (VEGF) serum concentration in non-Hodgkin's lymphoma patients;Stȩżenie naczyniowo-środbłonkowego czynnika wzrostu (VEGF) u chorych na chłoniaki nieziarnicze

Polskie Archiwum Medycyny Wewnetrznej

Volumn 112, Issue 2, 2004, Pages 919-923

  Wróbel, Tomasz ^a,b   Mazur, Grzegorz ^a   Usnarska Zubkiewicz, Lidia ^a   Kuliczkowski, Kazimierz ^a  

^a Klinika Hematologii   (Poland)

^b Katedra i Klinika Hematologii   (Poland)

Author keywords

Angiogenesis; Non Hodgkin lymphoma; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; VASCULOTROPIN; VINBLASTINE; VINCRISTINE; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PROGNOSIS; RISK FACTOR; B LYMPHOCYTE; BLOOD; METABOLISM; MIDDLE AGED;

ADULT; AGED; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4944256843     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Folkman J.: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1995, 1, 27.
2. Holmgren L., O'Reilly M.S., Folkman J.: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1995, 1, 149.
3. Iruela-Arispe M.L., Dvorak H.F.: Angiogenesis: A dynamic balance of stimulators and inhibitors. Thromb. Haemost., 1997, 78, 672.
4. Ferrara N.: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat., 1995, 36, 127.
5. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M.: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 1995, 146, 1029.
6. Yamamoto Y., Toi M., Kondo S. i wsp.: Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin. Cancer Res., 1996, 2, 821.
7. Salven P., Mäenpää H., Orpana A., Alitalo K., Joensuu H.: Serum VEGF is often elevated in disseminated cancer. Clin. Cancer Res., 1997, 6, 647.
8. Dirix L.Y., Vermeulen P.B., Hubens G. i wsp.: Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann. Oncol., 1996, 7, 843.
9. Belgore F.M., Lip G., Bareford D.: Plasma levels of vascular endothelial growth factor (VEGF) in haematological cancers. Br. J. Haematol., 2000, 110, 496.
10. Perez-Atayde A.R., Sallan S.E., Tedrow U.: Spectrum of tumor angiogenesis in bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol., 1997, 150, 815.
11. Hussong J.W., Rodgers G.M., Shami P.J.: Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 2000, 95, 309.
12. Vacca A., Ribatti D., Roncali L.: Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol., 1994, 87, 503.
13. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med., 1993, 329, 987.
14. Arias V., Soares F.A.: Vascular density (tumor angiogenesis) in non-Hodgkin's lymphomas and florid follicular hyperplasia: a morphometric study. Leuk. Lymphoma, 2000, 40, 157.
15. Ribatti D., Vacca A., Marzullo A. i wsp.: Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int. J. Cancer, 2000, 15, 171.
16. Salven P., Teerenhovi L., Joensuu H.: A High Pretreatment Serum Vascular Endothelial Growth Factor Concentration Is Associated With Poor Outcome in Non-Hodgkin's Lymphoma. Blood, 1997, 90, 3167.
17. Salven P., Orpana A., Teerenhovi L., Joensuu H.: Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood, 2000, 96, 3712.
18. Bertolini F., Paolucci M., Perccatori F. i wsp.: Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Brit. J. Haematol., 1999, 106, 504.
19. Margolin K., Gordon M.S., Holmgren E. i wsp.: Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced. Cancer: Pharmacologic and Long-Term Safety Data. J. Clin. Oncol., 2001, 19, 851.